Literature DB >> 17491693

Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach.

Damien Bresson1, Matthias von Herrath.   

Abstract

Entities:  

Year:  2006        PMID： 17491693      PMCID： PMC1783569          DOI： 10.1900/RDS.2005.2.187

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN： 1613-6071


× No keyword cloud information.
  16 in total

1.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Authors:  Kevan C Herold; William Hagopian; Julie A Auger; Ena Poumian-Ruiz; Lesley Taylor; David Donaldson; Stephen E Gitelman; David M Harlan; Danlin Xu; Robert A Zivin; Jeffrey A Bluestone
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

2.  Questioning four preconceived ideas on immunotherapy of clinical type 1 diabetes: lessons from recent CD3 antibody trials.

Authors:  Lucienne Chatenoud; Jean-François Bach
Journal:  Rev Diabet Stud       Date:  2005-11-10

3.  Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients.

Authors:  T H Renard; W S Andrews; M E Foster
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  CD4+CD25high regulatory T cells in human autoimmune diabetes.

Authors:  Amy L Putnam; Francesco Vendrame; Francesco Dotta; Peter A Gottlieb
Journal:  J Autoimmun       Date:  2005-01-12       Impact factor: 7.094

5.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

6.  Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation.

Authors:  C Ferran; K Sheehan; M Dy; R Schreiber; S Merite; P Landais; L H Noel; G Grau; J Bluestone; J F Bach
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

7.  Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor.

Authors:  M Alegre; P Vandenabeele; V Flamand; M Moser; O Leo; D Abramowicz; J Urbain; W Fiers; M Goldman
Journal:  Eur J Immunol       Date:  1990-03       Impact factor: 5.532

8.  Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.

Authors:  Matthias G von Herrath; Bryan Coon; Tom Wolfe; Lucienne Chatenoud
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

9.  Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody.

Authors:  K C Herold; J A Bluestone; A G Montag; A Parihar; A Wiegner; R E Gress; R Hirsch
Journal:  Diabetes       Date:  1992-03       Impact factor: 9.461

10.  A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

Authors:  Kevan C Herold; Stephen E Gitelman; Umesh Masharani; William Hagopian; Brygida Bisikirska; David Donaldson; Kristina Rother; Beverly Diamond; David M Harlan; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461
View more
  2 in total

1.  "Persistence of Diabetes" - Why Has Research into Type 1 Diabetes not Made Significant Advances?

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2007-02-10

2.  Induction of chimerism permits low-dose islet grafts in the liver or pancreas to reverse refractory autoimmune diabetes.

Authors:  Chunyan Zhang; Miao Wang; Jeremy J Racine; Hongjun Liu; Chia-Lei Lin; Indu Nair; Joyce Lau; Yu-An Cao; Ivan Todorov; Mark Atkinson; Defu Zeng
Journal:  Diabetes       Date:  2010-06-08       Impact factor: 9.461
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.